Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | IDH1 | O75874 | 8/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016193 | 0.87 | DAO (0.59) | DAOPDE3BPDE3APARP1IDH1 | |
| SCHEMBL7380955 | 0.78 | DAO (0.65) | DAOPDE3BPDE3APARP1HRH4 | |
| SCHEMBL828487 | 0.76 | BRD4 (0.59) | DAOIDH1 | |
| SCHEMBL14327807 | 0.76 | DAO (0.49) | DAOPDE3BPDE3AHRH4MAPT | |
| SCHEMBL24312093 | 0.75 | DAO (0.61) | DAOPDE3BPDE3APARP1HRH4 | |
| SCHEMBL21957317 | 0.75 | DAO (0.65) | DAOPDE3BPDE3APARP1HRH4 | |
| SCHEMBL3360519 | 0.75 | DAO (1.00) | DAOPDE3BPDE3APARP1HRH4 | |
| SCHEMBL31475468 | 0.75 | DAO (0.65) | DAOPDE3BPDE3APARP1HRH4 | |
| SCHEMBL22017082 | 0.74 | DAO (0.59) | DAOPDE3BPDE3APARP1HRH4 | |
| SCHEMBL4310842 | 0.74 | DAO (0.59) | DAOPDE3BPDE3APARP1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | DAO 4439/4885PDE3B 335/4885PDE3A 764/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | DAO 4497/4885PDE3B 337/4885PDE3A 803/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | DAO 4307/4885PDE3B 87/4885PDE3A 266/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | DAO 4439/4885PDE3B 335/4885PDE3A 764/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | DAO 4307/4885PDE3B 87/4885PDE3A 266/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | DAO 4439/4885PDE3B 335/4885PDE3A 764/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | DAO 4523/4885PDE3B 248/4885PDE3A 912/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | DAO 4281/4885PDE3B 42/4885PDE3A 62/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | DAO 4439/4885PDE3B 335/4885PDE3A 764/4885 |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | DAO 4281/4885PDE3B 42/4885PDE3A 62/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | DAO 4307/4885PDE3B 87/4885PDE3A 266/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | DAO 4281/4885PDE3B 42/4885PDE3A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.